Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (APCS-01)
jRCTs021200003Phase 2Recruiting
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC) and pancreatic adenosquamous carcinoma (PASC). Primary endpoint: Relapse-free survival time. Started Sep 2020; status: recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic adenosquamous carcinoma (PASC)
Beyond the preview
Go deeper on jRCTs021200003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021200003.